Protease, Polymerase, and Assembly Inhibitors for the Treatment of Hepatitis C Virus Infection
M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson in Kucers’ The Use of Antibiotics, 2017
CYP3A is involved in the elimination of asunaprevir. Therefore, moderate or strong inducers of CYP3A may decrease the plasma levels of asunaprevir, and moderate or strong inhibitors of CYP3A may increase the plasma levels of asunaprevir. Asunaprevir is also a substrate of PGP. OATP1B1 and OATP2B1 are involved in the liver distribution of asunaprevir. Therefore, strong inhibitors of OATP-mediated transport may increase the plasma concentrations of asunaprevir and may decrease its therapeutic effect by reducing distribution to the liver. Clinically relevant examples of OATP inhibitors include ritonavir (OATPB1/B3/A2), atazanavir (OATPB1/B3), cyclosporine A (OATP1B1/B3/A2, OATP2B1), rifampicin (OATP1B1/B3, OATP2B1), lovastatin (OATP1BI), pravastatin (OATP1BI), and simvastatin (OATP1BI) (International Transporter, et al., 2010; Karlgren et al. 2012). Up-to-date drug–drug interaction information can be accessed via hep-druginteractions.org.
Protease inhibitor therapy for hepatitis C virus-infection
Published in Expert Opinion on Pharmacotherapy, 2018
Asunaprevir is a second-generation NS3 protease inhibitor and was approved in combination with daclatasvir (DCV) in Japan for the treatment of HCV genotype 1-infected patients. ASV is active against genotype 1, 4, 5, and 6 in vitro [44]. The HALLMARK-DUAL trial investigated the safety and efficacy of DCV, a NS5A inhibitor, once daily plus ASV 100 mg twice daily or placebo for 12 weeks in chronically infected patients with HCV genotype 1b with or without cirrhosis. Even though SVR rates were all-over high in the study population, there were statistically significant lower SVR rates for patients with the presence of preexisting baseline RASs compared to patients without any baseline RASs (39% vs. 92% SVR), respectively. Baseline RASs were detected in 13% of the patients [45]. Overall SVR rates were about 80%. ASV was not approved in the USA and Europe.
An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery
Published in Expert Opinion on Drug Discovery, 2023
Several broad-spectrum anti-CoV drugs were repurposed from hepatitis C (HCV) agents [84]. Asunaprevir had IC50 values of 31 to 53.9 µM against different strains of CoVs, suggesting a broad-spectrum application for the drug. F0213 was found to be a broad-spectrum inhibitor that inhibited the PLpro of MERS-CoV and SARS-CoV1 and 2 [32]. F0213 is a competitive inhibitor of MERS-PLpro and binds to the 271E position. F0213 inserts itself into the shallow gap between the α7 and β8 residues of MERS-PLpro, leading to a change in the conformation. In addition to its inhibitory properties, it promoted host immunity by suppressing the deubiquitinating activity of PLpro. However, in the case of SARS-2-PLpro, F0213 became bound to the BL2 loop instead of the cleft between the α7 and β8 residues of MERS-PLpro. Therefore, it blocked the entrance of the substrate at the active site. Hence, F0213 could be utilized as a potential antiviral drug against a broad range of CoVs.
Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series
Published in Modern Rheumatology, 2020
Takashi Kida, Atsushi Umemura, Shunya Kaneshita, Risa Sagawa, Takuya Inoue, Shogo Toyama, Makoto Wada, Masataka Kohno, Ryo Oda, Tohru Inaba, Yoshito Itoh, Yutaka Kawahito
The SVR rate at EoT24 for the first course of DAA therapy was 89% (16/18). After starting DAAs, all patients showed undetectable HCV-RNA by week 8; however, the reappearance of HCV-RNA was observed in two patients treated with daclatasvir + asunaprevir against HCV genotype 1b. Reappearance in one patient occurred during treatment (a patient with RA treated with sulfasalazine; DAAs were discontinued at week 16), so-called ‘virological breakthrough’, and reappearance in the other patient occurred 4 weeks after EoT (a patients with systemic lupus erythematosus (SLE) treated with tacrolimus and prednisolone), so-called ‘virological relapse’. Both patients received a second course of DAA therapy using a different regimen, and achieved SVR during the study period (see Supplementary Table S1, available with the online version of this article). Regarding these two patients, data from the second course of DAA therapy were used for analyses when evaluating the effect of HCV elimination.
Related Knowledge Centers
- Daclatasvir
- Drug Development
- Enzyme Inhibitor
- Hepatitis C
- Ribavirin
- Phases of Clinical Research
- Hepatitis C Virus NONstructural Protein 3
- Pegylated Interferon